232 related articles for article (PubMed ID: 22065207)
21. Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline.
Youdim MB; Maruyama W; Naoi M
Drugs Today (Barc); 2005 Jun; 41(6):369-91. PubMed ID: 16110345
[TBL] [Abstract][Full Text] [Related]
22. Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease.
Chen JJ; Ly AV
Am J Health Syst Pharm; 2006 May; 63(10):915-28. PubMed ID: 16675649
[TBL] [Abstract][Full Text] [Related]
23. Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.
Weinreb O; Amit T; Bar-Am O; Youdim MB
Prog Neurobiol; 2010 Nov; 92(3):330-44. PubMed ID: 20600573
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
25. [A comparison of the pharmacology of (-)-deprenyl to N-methylpropargylamine-1-aminoindane (J-508) and rasagiline, the desmethyl-analogue of J-508].
Miklya I
Neuropsychopharmacol Hung; 2008 Mar; 10(1):15-22. PubMed ID: 18771016
[TBL] [Abstract][Full Text] [Related]
26. Rasagiline, a monoamine oxidase-B inhibitor, protects NGF-differentiated PC12 cells against oxygen-glucose deprivation.
Abu-Raya S; Blaugrund E; Trembovler V; Shilderman-Bloch E; Shohami E; Lazarovici P
J Neurosci Res; 1999 Nov; 58(3):456-63. PubMed ID: 10518120
[TBL] [Abstract][Full Text] [Related]
27. Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells.
Nagatsu T; Sawada M
J Neural Transm Suppl; 2006; (71):53-65. PubMed ID: 17447416
[TBL] [Abstract][Full Text] [Related]
28. The New Inhibitor of Monoamine Oxidase, M30, has a Neuroprotective Effect Against Dexamethasone-Induced Brain Cell Apoptosis.
Johnson S; Tazik S; Lu D; Johnson C; Youdim MB; Wang J; Rajkowska G; Ou XM
Front Neurosci; 2010; 4():180. PubMed ID: 21103012
[TBL] [Abstract][Full Text] [Related]
29. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
Guay DR
Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
[TBL] [Abstract][Full Text] [Related]
30. (-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase.
Tatton WG; Wadia JS; Ju WY; Chalmers-Redman RM; Tatton NA
J Neural Transm Suppl; 1996; 48():45-59. PubMed ID: 8988461
[TBL] [Abstract][Full Text] [Related]
31. Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor.
Finberg JP; Takeshima T; Johnston JM; Commissiong JW
Neuroreport; 1998 Mar; 9(4):703-7. PubMed ID: 9559942
[TBL] [Abstract][Full Text] [Related]
32. Selegiline and rasagiline: twins or distant cousins?
Knudsen Gerber DS
Consult Pharm; 2011 Jan; 26(1):48-51. PubMed ID: 21224199
[TBL] [Abstract][Full Text] [Related]
33. The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo.
Youdim MB; Wadia A; Tatton W; Weinstock M
Ann N Y Acad Sci; 2001 Jun; 939():450-8. PubMed ID: 11462801
[TBL] [Abstract][Full Text] [Related]
34. [Possible mechanism of selective inhibition of rat liver mitochondrial monoamine oxidase by chlorgiline and deprenyl].
Severina IS
Biokhimiia; 1979 Feb; 44(2):195-207. PubMed ID: 435561
[TBL] [Abstract][Full Text] [Related]
35. Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members.
Weinreb O; Bar-Am O; Amit T; Chillag-Talmor O; Youdim MB
FASEB J; 2004 Sep; 18(12):1471-3. PubMed ID: 15247150
[TBL] [Abstract][Full Text] [Related]
36. Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease.
Naoi M; Maruyama W
Expert Rev Neurother; 2009 Aug; 9(8):1233-50. PubMed ID: 19673610
[TBL] [Abstract][Full Text] [Related]
37. The neuronal survival effects of rasagiline and deprenyl on fetal human and rat ventral mesencephalic neurones in culture.
Goggi J; Theofilopoulos S; Riaz SS; Jauniaux E; Stern GM; Bradford HF
Neuroreport; 2000 Dec; 11(18):3937-41. PubMed ID: 11192605
[TBL] [Abstract][Full Text] [Related]
38. Electropharmacograms of rasagiline, its metabolite aminoindan and selegiline in the freely moving rat.
Dimpfel W; Hoffmann JA
Neuropsychobiology; 2010; 62(4):213-20. PubMed ID: 20714170
[TBL] [Abstract][Full Text] [Related]
39. Selective inhibitors of monoamine oxidase type B and the "cheese effect".
Finberg JP; Gillman K
Int Rev Neurobiol; 2011; 100():169-90. PubMed ID: 21971008
[TBL] [Abstract][Full Text] [Related]
40. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives.
Mandel S; Weinreb O; Amit T; Youdim MB
Brain Res Brain Res Rev; 2005 Apr; 48(2):379-87. PubMed ID: 15850677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
